Table 1. Clinical trials in multiple myeloma and Waldenström’s macroglobulinemia patients with CAM as cancer treatment.

Disease	Targets	Drug combination (with selected references)
Breast cancer	Pro-inflammatory cytokines, monocytes … During and after surgery	NSAIDs [18], aspirin [19], beta-blockers [20]
NSCLC	Pro-inflammatory cytokines, monocytes … During and after surgery and/or radiotherapy	NSAIDs [13, 14], aspirin [21], cimetidine [22], beta-blockers [14]
NSCLC	Angiogenesis and endothelial cells	Metronomic [6, 23] or maintenance [1, 2] chemotherapy, aspirin [19, 24]
All solid tumours, highly inflammatory (e.g. high neutrophils to lymphocytes Ratio)	Pro-inflammatory cytokines, monocytes, dendritic cells, T-cell trafficking …	NSAIDs [13], metronomic chemotherapy [23]
Melanoma and other immunogenic tumours	Immune cells of the tumour environment (effector T-cells, Myeloid-derived suppressor cells, regulator T-cells, macrophages)	Immune checkpoint inhibitors [25], cellular immunotherapies [26]